A revolution in diabetes treatment? The advantage found in drugs like Ozempic

An observational study of 256,000 adults in the US found that GLP-1 drugs (like Ozempic) are associated with a 31% reduction in the risk of developing type 2 diabetes, an increased chance of blood sugar normalization, and a reduced risk of heart attack, stroke, and death. Researchers emphasize this is an additional option, not a replacement for metformin.

A large-scale observational study analyzing medical records of 256,000 US adults with prediabetes and obesity points to significant benefits of GLP-1 drugs (like Ozempic) compared to standard metformin treatment. Patients in the GLP-1 group were 1.5 times more likely to return blood sugar levels to normal and had a 31% lower risk of progressing to type 2 diabetes. Additionally, there was a 41% reduction in all-cause mortality, 15% fewer heart attacks, 20% fewer strokes, and 25% less heart failure. However, researchers stress this is an observational study that does not prove causality, and metformin remains an effective, cheap, and safe drug. The key message is that prediabetes is a reversible condition, and lifestyle changes are the first line of defense. The article presents the findings as a basis for discussion between patient and doctor about additional treatment options.